Current Good Manufacturing Practice Production of an Oncolytic Recombinant Vesicular Stomatitis Viral Vector for Cancer Treatment
Authors:
- 1 April 2011
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 22 (4) , 489-497
Abstract
Vesicular stomatitis virus (VSV) is an oncolytic virus currently being investigated as a promising tool to treat cancer because of its ability to selectively replicate in cancer cells. To enhance the oncolytic property of the nonpathologic laboratory strain of VSV, we generated a recombinant vector [rVSV(MΔ51)-M3] expressing murine gammaherpesvirus M3, a secreted viral chemokine-binding protein that binds to a broad range of mammalian chemokines with high affinity. As previously reported, when rVSV(MΔ51)-M3 was used in an orthotopic model of hepatocellular carcinoma (HCC) in rats, it suppressed inflammatory cell migration to the virus-infected tumor site, which allowed for enhanced intratumoral virus replication leading to increased tumor necrosis and substantially prolonged survival. These encouraging results led to the development of this vector for clinical translation in patients with HCC. However, a scalable current Good Manufacturing Practice (cGMP)-compliant manufacturing process has not been described for this vector. To produce the quantities of high-titer virus required for clinical trials, a process that is amenable to GMP manufacturing and scale-up was developed. We describe here a large-scale (50-liter) vector production process capable of achieving crude titers on the order of 109 plaque-forming units (PFU)/ml under cGMP. This process was used to generate a master virus seed stock and a clinical lot of the clinical trial agent under cGMP with an infectious viral titer of approximately 2 × 1010 PFU/ml (total yield, 1 × 1013 PFU). The lot has passed all U.S. Food and Drug Administration-mandated release testing and will be used in a phase 1 clinical translational trial in patients with advanced HCC.Keywords
This publication has 38 references indexed in Scilit:
- TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancerGene Therapy, 2010
- A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell linesApoptosis, 2009
- A Hyperfusogenic F Protein Enhances the Oncolytic Potency of a Paramyxovirus Simian Virus 5 P/V Mutant without Compromising Sensitivity to Type I InterferonJournal of Virology, 2008
- Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon CancerPLOS ONE, 2008
- rVSV(MΔ51)-M3 Is an Effective and Safe Oncolytic Virus for Cancer TherapyHuman Gene Therapy, 2008
- Arming parvoviruses with CpG motifs to improve their oncosuppressive capacityInternational Journal of Cancer, 2008
- The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTRCancer Gene Therapy, 2007
- Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963Journal of Clinical Investigation, 2007
- Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models.Journal of Clinical Investigation, 1993
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977